171 results
Page 6 of 9
8-K
EX-99.1
v7ynz9
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-99.1
03hfo
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-10.1
yq2rb0sl9 2d755
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
r6wj9 bdmga0of54
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
i9gxlp lsd7n
1 Aug 19
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
7:23am
8-K
EX-99.1
s4hg7tm
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-99.1
23wdi0indn8vu
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
irz8yp9v3hpg rjyj
22 Jul 19
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
8:08am
8-K
EX-99.1
v7ja s3yfrz
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-10.1
n426jsouj1
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
nkikk9rszjsvx7ekrh
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
unqlwtp273g2ed68wzq
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
8nvxxz ayvu
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
bj9u 5agjj
6 May 19
Adaptimmune Reports First Quarter 2019 Financial Results
7:38am
8-K
EX-99.1
z8x0wai
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
EX-99.1
iahw2b5t85lqbl es6fv
2 May 19
Other Events
7:10am